GlassScriptPhysician profile
Jeffrey Matthew Martin
NPI 1942379573
$833.43
in general payments reported to CMS, 2019-2025
19 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.56 · 2020: $49.12 · 2021: $83.31 · 2022: $166 · 2023: $199 · 2024: $67.42 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $83.14 | 2022-2023 | |
| Boston Scientific Corporation | $73.54 | 2023 | Watchman Flx |
| Pfizer INC. | $68.70 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.46 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $37.93 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $32.50 | 2022-2025 | Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $32.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.37 | 2020 | |
| Genentech USA, INC. | $22.65 | 2019 | |
| Abbott Laboratories | $21.97 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2021 | |
| Alk-Abello, INC | $20.33 | 2025 | Neffy, Odactra, Grastek |
| Lilly USA, LLC | $18.07 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $15.82 | 2024 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $15.73 | 2023 | Lyvispah |
| Medtronic, INC. | $15.49 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $14.76 | 2025 | Voquezna |
| Amarin Pharma, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.